CL2020002546A1 - Compuestos dirigidos a brm y métodos de uso asociados - Google Patents

Compuestos dirigidos a brm y métodos de uso asociados

Info

Publication number
CL2020002546A1
CL2020002546A1 CL2020002546A CL2020002546A CL2020002546A1 CL 2020002546 A1 CL2020002546 A1 CL 2020002546A1 CL 2020002546 A CL2020002546 A CL 2020002546A CL 2020002546 A CL2020002546 A CL 2020002546A CL 2020002546 A1 CL2020002546 A1 CL 2020002546A1
Authority
CL
Chile
Prior art keywords
target protein
present disclosure
brm
compounds
associated methods
Prior art date
Application number
CL2020002546A
Other languages
English (en)
Inventor
P Crew Andrew
Wang Jing
Berlin Michael
Dragovich Peter
Chen Huifen
Staben Leanna
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CL2020002546A1 publication Critical patent/CL2020002546A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación se refiere a compuestos bifuncionales, que encuentran utilidad como moduladores de SMARCA2 o BRM (proteína diana). En particular, la presente divulgación está dirigida a compuestos bifuncionales, que contienen en un extremo un ligando que se une a la ubiquitina ligasa de Von Hippel-Lindau E3, y en el otro extremo un resto que se une a la proteína diana, de modo que la proteína diana es colocada cerca de la ubiquitina ligasa para efectuar la degradación (e inhibición) de la proteína diana. La presente divulgación exhibe una amplia gama de actividades farmacológicas asociadas con la degradación / inhibición de la proteína diana. Las enfermedades o trastornos que resultan de la agregación o acumulación de la proteína diana se tratan o se previenen con compuestos y composiciones de la presente divulgación.
CL2020002546A 2018-04-01 2020-10-01 Compuestos dirigidos a brm y métodos de uso asociados CL2020002546A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862651186P 2018-04-01 2018-04-01
US201962797754P 2019-01-28 2019-01-28

Publications (1)

Publication Number Publication Date
CL2020002546A1 true CL2020002546A1 (es) 2021-01-29

Family

ID=66175525

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002546A CL2020002546A1 (es) 2018-04-01 2020-10-01 Compuestos dirigidos a brm y métodos de uso asociados

Country Status (17)

Country Link
US (2) US20190300521A1 (es)
EP (1) EP3774789A1 (es)
JP (2) JP2021520350A (es)
KR (2) KR102697733B1 (es)
CN (1) CN112166114B (es)
AU (3) AU2019249849C1 (es)
BR (1) BR112020020196A2 (es)
CA (1) CA3094305A1 (es)
CL (1) CL2020002546A1 (es)
CO (1) CO2020013762A2 (es)
CR (1) CR20200527A (es)
IL (1) IL277677A (es)
MX (2) MX2020010368A (es)
PE (1) PE20212108A1 (es)
PH (1) PH12020500663A1 (es)
SG (1) SG11202008898UA (es)
WO (1) WO2019195201A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240095318A (ko) 2018-04-04 2024-06-25 아비나스 오퍼레이션스, 인코포레이티드 단백질분해 조절제 및 연관된 사용 방법
EP3784665A4 (en) * 2018-04-26 2022-01-26 Aurigene Discovery Technologies Limited PYRIDAZINE DERIVATIVES AS SMARCA2/4 DEGRADERS
EP3787747A4 (en) * 2018-04-30 2022-01-12 Dana-Farber Cancer Institute, Inc. POLYBROMO-1 (PBRM1) SMALL MOLECULE DEGRADATION PRODUCTS
JP7297053B2 (ja) 2018-08-20 2023-06-23 アルビナス・オペレーションズ・インコーポレイテッド 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
TW202037381A (zh) 2018-10-24 2020-10-16 瑞士商赫孚孟拉羅股份公司 綴合化學降解誘導劑及使用方法
CN113453679A (zh) 2018-12-20 2021-09-28 C4医药公司 靶向蛋白降解
CN114867727A (zh) 2019-07-17 2022-08-05 阿尔维纳斯运营股份有限公司 Tau蛋白靶向化合物及相关使用方法
CN114787159B (zh) * 2019-10-01 2024-09-27 阿尔维纳斯运营股份有限公司 Brm靶向化合物及相关使用方法
IL292153A (en) * 2019-10-16 2022-06-01 Cemm Forschungszentrum Fur Molekulare Medizin Gmbh Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof
CN114599428A (zh) * 2019-10-28 2022-06-07 豪夫迈·罗氏有限公司 双功能化合物
EP4051674A1 (en) * 2019-10-29 2022-09-07 F. Hoffmann-La Roche AG Bifunctional compounds for the treatment of cancer
BR112022012410A2 (pt) 2019-12-23 2022-08-30 Kymera Therapeutics Inc Degradadores smarca e usos dos mesmos
TW202140485A (zh) 2020-01-29 2021-11-01 美商福宏治療公司 化合物及其用途
CA3166404A1 (en) * 2020-01-29 2021-08-05 Matthew Netherton A bifunctional molecule comprising an active compound,a linker and a degradation moiety, and its use to treat disorders associated with baf complex function
CN115279370B (zh) 2020-03-05 2025-01-10 C4医药公司 用于brd9的靶向降解的化合物
KR20230037549A (ko) * 2020-06-09 2023-03-16 프렐루드 테라퓨틱스, 인코포레이티드 Brm 표적화 화합물 및 관련 사용 방법
MX2023000888A (es) 2020-07-21 2023-02-22 Genentech Inc Inductores quimicos de degradacion conjugados con anticuerpo de brm y metodos de estos.
US11787800B2 (en) 2020-07-29 2023-10-17 Foghorn Therapeutics Inc. BRD9 degraders and uses thereof
JP2023536504A (ja) * 2020-08-04 2023-08-25 オーリジーン オンコロジー リミテッド Ｓｍａｒｃａ２および／またはｓｍａｒｃａ４分解剤としての６置換ピリダジン化合物
MX2023005301A (es) 2020-11-06 2023-07-18 Prelude Thereapeutics Incorporated Compuestos dirigidos a brm y metodos de uso asociados.
EP4259144A1 (en) * 2020-12-09 2023-10-18 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
MX2023008296A (es) 2021-01-13 2023-09-29 Monte Rosa Therapeutics Inc Compuestos de isoindolinona.
TW202241855A (zh) * 2021-01-27 2022-11-01 美商富曼西公司 用於防治無脊椎有害生物之唑類化合物
MX2023011940A (es) 2021-04-16 2023-12-07 Arvinas Operations Inc Moduladores de la proteolisis bcl6 y metodos de uso asociados.
EP4333899A1 (en) 2021-05-05 2024-03-13 Biogen MA Inc. Compounds for targeting degradation of bruton's tyrosine kinase
AU2022272181A1 (en) * 2021-05-10 2023-11-02 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2023283263A1 (en) 2021-07-06 2023-01-12 Foghorn Therapeutics Inc. Citrate salt, pharmaceutical compositions, and methods of making and using the same
JP2024525580A (ja) 2021-07-07 2024-07-12 バイオジェン・エムエイ・インコーポレイテッド Ｉｒａｋ４タンパク質の分解をターゲティングするための化合物
MX2024000395A (es) 2021-07-07 2024-04-05 Biogen Ma Inc Compuestos para la degradacion selectiva de las proteinas irak4.
US20240336612A1 (en) * 2021-07-13 2024-10-10 Prelude Therapeutics Incorporated BRM Targeting Compounds And Associated Methods Of Use
CN118696045A (zh) * 2021-11-23 2024-09-24 南京再明医药有限公司 Brm选择性降解剂化合物及其应用
WO2023097031A1 (en) * 2021-11-24 2023-06-01 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
EP4436965A1 (en) * 2021-11-24 2024-10-02 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
WO2023129506A1 (en) * 2021-12-28 2023-07-06 Board Of Regents, The University Of Texas System Potent and selective smarca2 degrading chimeric molecules as cancer therapeutics
AR128330A1 (es) 2022-01-26 2024-04-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
AR128331A1 (es) 2022-01-26 2024-04-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpos y métodos de estos
AU2023295547A1 (en) 2022-06-16 2025-01-09 Prelude Therapeutics Incorporated Kat6 targeting compounds with ubiquitin ligase binding moiety
CN119384414A (zh) * 2022-06-30 2025-01-28 甘李药业股份有限公司 一种用作smarca2/4抑制剂的化合物及其应用
CN115353468B (zh) * 2022-08-19 2023-06-30 安阳工学院 一种对甲苯磺酰氧基取代低聚乙二醇丙酸叔丁酯的制备方法
US20240190886A1 (en) 2022-11-15 2024-06-13 Prelude Therapeutics Incorporated BRM Targeting Compounds and Associated Methods of Use
WO2024179529A1 (zh) * 2023-02-28 2024-09-06 上海海雁医药科技有限公司 取代的三环衍生物及其药物组合物和用途
WO2024254532A1 (en) 2023-06-08 2024-12-12 Nurix Therapeutics, Inc. Bifunctional azines conjogates as selective degraders of smarca2 and therapeutic uses thereof
WO2024256574A1 (en) * 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Process for preparing macrocyclic btk inhibitors
WO2024256988A1 (en) 2023-06-14 2024-12-19 Astrazeneca Ab Smarca2 degraders and uses thereof
WO2024257012A1 (en) 2023-06-14 2024-12-19 Astrazeneca Ab 3-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]-3,8-diazabicyclo[3.2.1]octane derivatives as smarca2 degrading protacs for the treatment of cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
RU2666530C2 (ru) * 2012-01-12 2018-09-11 Йейл Юниверсити Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы
KR20210132233A (ko) * 2014-04-14 2021-11-03 아비나스 오퍼레이션스, 인코포레이티드 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
WO2016105518A1 (en) * 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US9694084B2 (en) * 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
KR102564925B1 (ko) * 2015-01-20 2023-08-07 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
MA41598A (fr) * 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
CN108601764A (zh) 2015-03-18 2018-09-28 阿尔维纳斯股份有限公司 用于靶蛋白的增强降解的化合物和方法
MX2018000360A (es) * 2015-07-10 2018-06-11 Arvinas Inc Moduladores basados en mdm2 de proteolisis y metodos de uso asociados.
KR20180029061A (ko) * 2015-07-13 2018-03-19 아비나스 인코포레이티드 단백질 분해의 알라닌계 조절인자 및 관련된 이용 방법
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
WO2017079267A1 (en) * 2015-11-02 2017-05-11 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same
AU2018215212B2 (en) 2017-01-31 2022-06-02 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
CN107698657A (zh) * 2017-09-26 2018-02-16 中国药科大学 基于vhl配体和bet抑制剂诱导bet降解的双功能分子及其制备和应用

Also Published As

Publication number Publication date
MX2024000329A (es) 2024-01-25
AU2024203058A1 (en) 2024-05-30
AU2019249849B2 (en) 2022-03-17
US20190300521A1 (en) 2019-10-03
RU2020135754A3 (es) 2022-05-04
US20240076295A1 (en) 2024-03-07
BR112020020196A2 (pt) 2021-01-26
CR20200527A (es) 2021-04-09
MX2020010368A (es) 2021-01-08
KR20210005037A (ko) 2021-01-13
RU2020135754A (ru) 2022-05-04
AU2019249849A1 (en) 2020-10-01
KR20240130153A (ko) 2024-08-28
JP2023071767A (ja) 2023-05-23
WO2019195201A1 (en) 2019-10-10
CO2020013762A2 (es) 2021-01-18
PH12020500663A1 (en) 2021-06-07
NZ767872A (en) 2024-04-26
IL277677A (en) 2020-11-30
KR102697733B1 (ko) 2024-08-26
AU2022204042A1 (en) 2022-06-30
CN112166114A (zh) 2021-01-01
SG11202008898UA (en) 2020-10-29
CN112166114B (zh) 2024-11-19
JP2021520350A (ja) 2021-08-19
CA3094305A1 (en) 2019-10-10
PE20212108A1 (es) 2021-11-04
EP3774789A1 (en) 2021-02-17
AU2019249849C1 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
CL2020002546A1 (es) Compuestos dirigidos a brm y métodos de uso asociados
CO2019009145A2 (es) Moduladores de la proteolisis del receptor de estrogeno y métodos asociados de uso
CO2019005712A2 (es) Protac dirigidos a la proteína tau y métodos asociados de uso
CO2019007091A2 (es) Derivados de tetrahidronaftaleno y tetrahidroisoquinolina como degradadores del receptor de estrogeno
MX2022004526A (es) Moléculas bifuncionales que contienen una porción de unión a la ligasa de ubiquitina e3 unida a una porción de direccionamiento a bcl6.
CO2019007892A2 (es) Moléculas quiméricas dirigidas a la proteólisis del egfr y métodos asociados de uso
CO2019007894A2 (es) Compuestos y métodos para la degradación dirigida de polipéptidos de fibrosarcoma acelerado rápidamente
CO2020013864A2 (es) Moduladores de la proteólisis y métodos asociados de uso
CO2021000151A2 (es) Inhibidores de pd-1/pd-l1
CO2020009861A2 (es) Inhibidores pd-1/pd-l1
DOP2019000266A (es) Inhibidores de pd-1/pd-l1
CL2023003021A1 (es) Moduladores de la proteólisis bcl6 y métodos de uso asociados,
MX2021002559A (es) Compuestos policiclicos y metodos para la degradacion dirigida de polipeptidos de fibrosarcoma rapidamente acelerado.
BR112018067408A2 (pt) formas sólidas de um inibidor de acc de tienopirimidinadiona e métodos para a produção das mesmas
CL2021003196A1 (es) Terapias combinadas dirigidas a pd-1, tim-3, y lag-3 (divisional de solicitud n° 201902850)
BR112017028394A2 (pt) composto, composição, e, métodos para induzir a degradação de uma proteína-alvo em uma célula e para tratar um estado doente ou uma condição doente.
BR112018012756A2 (pt) compostos heterocíclicos como imunomoduladores
BR112019000693A2 (pt) composições de muc1- car e métodos para uso
CL2021000650A1 (es) Moduladores de la expresión de pnpla3
UY38352A (es) Inhibidores de integrina alfavbeta6
CO2021007006A2 (es) Moduladores de la expresión de irf5
MX2020003554A (es) Moduladores de la expresion de enac.
EA202092733A1 (ru) Ингибиторы pd-1/pd-l1
EA202091694A1 (ru) Ингибиторы pd-1/pd-l1
EA201992045A1 (ru) Ингибиторы pd-1/pd-l1